Acromegaly: current view

Czech version

Authors: Michal Kršek
Authors‘ workplace: III. interní klinika – klinika endokrinologie a metabolizmu 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2015; 61(10): 900-904
Category: Reviews

Overview

Acromegaly is a rare disorder caused by autonomous oversecretion of growth hormone mostly by pituitary adenoma. Untreated acromegaly leads to significantly increased morbidity and mortality and impaired quality of life. Early diagnosis and treatment is therefore essential for improvement of patients’ prognosis and management of acromegaly should be concentrated in specialized centres. Present article summarizes current view on diagnosis and treatment of acromegaly.

Key words:
acromegaly – diagnosis – presentation – treatment

Sources

1. Marie P. On two case of acromegaly: marked hypertrophy of the upper and Loir limbs and the head. Rev Med 1886; 6: 297–333.

2. Alexander L, Appleton D, Hall R et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12(1): 71–79.

3. Begtsson BA, Eden S, Ernest I et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955–1984. Acta Medica Scand 1988; 223(4): 327–335.

4. Melmed S, Kleinberg D. Anterior Pituitary. In: Kronenberg HM, Melmed S, Polonsky KS et al. Williams textbook of endocrinology. Philadelphia: Saunders Elsevier 200: 155–261. ISBN: 9781416029113.

5. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988; 67(1): 69–73.

6. Katznelson L, Laws ER Jr, Melmed S et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99(11): 3933–3951.

7. Kan E, Kan EK, Atmaca A et al. Visual field defects in 23 acromegalic patients. Int Ophthalmol 2013; 33(5): 521–525.

8. McLaughlin N, Laws ER, Oyesiku NM et al. Pituitary centers of excellence. Neurosurgery 2012; 71(5): 916–924.

9. Jane jr. JA, Starke RM, Elzoghby MA et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications and predictors of outcome. J Clin Endocrinol Metab 2011; 96(9): 2732–2740.

10. Starke RM, Raper DM, Payne SC et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013; 98(8): 3190–3198.

11. Caron PJ, Bevan JS, Petersenn S et al. Tumor shrinkagewith lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014; 99(4): 1282–1290.

12. Giustina A, Mazziotti G, Torri V et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012; 7(5): e36411. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0036411>.

13. Giustina A, Bonadonna S, Bugari G et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on convenctional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009; 161(2): 331–338.

14. Gadelha MR, Bronstein MD, Brue T et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2(11): 875–84.

15. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295): 1754–1759.

16. Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156(1): 75–82.

17. Neggers SJ, de Herder WW, Feelders RA et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011; 14(3): 253–258.

18. Ježková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly – long-term experience. Clin Endocrinol (Oxf) 2006; 64(5): 588–595.